<DOC>
	<DOCNO>NCT00878657</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving intensity-modulated radiation therapy together gemcitabine may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose intensity-modulated radiation therapy see well work give together gemcitabine treat patient locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Intensity-Modulated Radiation Therapy Gemcitabine Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>The study terminate early due slow accrual phase I portion hte study open . The phase study revise phase I study . OBJECTIVES : - To determine maximum tolerate dose ( MTD ) intensity-modulated radiotherapy deliver gross tumor volume administer gemcitabine hydrochloride patient locally advance pancreatic carcinoma . ( Phase I ) - To define dose-limiting toxicity regimen patient . ( Phase I ) - To determine local control patient treat MTD ( determined phase I ) . ( Phase II ) - To compare disease-free survival time progression patient historical control . ( Phase II ) OUTLINE : This multicenter phase I , dose-escalation study intensity-modulated radiotherapy , follow phase II study . - Induction chemotherapy : Patients receive gemcitabine hydrochloride IV day 1 , 8 , 15 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients undergo CT scan . Patients evidence metastatic disease proceed chemoradiotherapy . - Chemoradiotherapy : Beginning 1-2 week completion induction chemotherapy , patient undergo intensity-modulated radiotherapy daily 5 day week gemcitabine hydrochloride IV 30 minute weekly 5 week absence disease progression unacceptable toxicity . Patients whose disease remain unresectable proceed adjuvant chemotherapy . - Adjuvant chemotherapy : Beginning 4-6 week completion chemoradiotherapy , patient receive gemcitabine hydrochloride induction chemotherapy . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm adenocarcinoma poorly differentiate carcinoma pancreas , ampulla Vater , distal bile duct Locally advance disease Medically inoperable , unresectable , borderline resectable disease No previously resect disease ( i.e. , status postpancreaticoduodenotomy ) No nonadenocarcinoma , adenosquamous carcinoma , islet cell carcinoma , cyst adenoma , cystadenocarcinoma , carcinoid tumor , duodenal carcinoma No lesion tail pancreas and/or splenic artery/vein involvement/encasement No recurrent metastatic ( M1 ) disease PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % WBC &gt; 3,000/μL Platelet count &gt; 100,000/μL Bilirubin ≤ 2 mg/dL SGOT &lt; 5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Adequate oral nutrition ( e.g. , ≥ 1,500 calories/day , stable weight ≥ 2 week , ≤ 5 % weight loss ) No active malignancy within past 3 year , except cervical carcinoma situ nonmelanoma skin cancer remove No severe , active comorbidity , include follow : Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require IV antibiotic time study registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization within past month preclude study therapy time study registration Active hepatitis , decompensated cirrhosis , clinically significant liver failure Other severe comorbid condition , determine principal investigator PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy No prior radiotherapy upper abdominal site No concurrent prophylactic colonystimulating factor radiotherapy No concurrent warfarin No concurrent chemotherapy , immunotherapy , hormonal cancer therapy , radiotherapy , surgery cancer , experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>